CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:

NDA 022410/S-011

Trade Name: **SUBOXONE**

Generic Name: **Buprenorphine Hydrochloride; Naloxone Hydrochloride**

Sponsor: **Reckitt Benckiser Pharmaceuticals, Inc.**

Approval Date: 08/08/2013

Indications: SUBOXONE sublingual film is indicated for maintenance treatment of opioid dependence and should be used as part of a complete treatment plan to include counseling and psychosocial support.

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

NDA 022410/S-011

CONTENTS

Reviews / Information Included in this NDA Review.

Approval Letter	**X**
Other Action Letters	
Labeling	
Summary Review	
Officer/Employee List	
Office Director Memo	
Cross Discipline Team Leader Review	
Medical Review(s)	
Chemistry Review(s)	**X**
Environmental Assessment	
Pharmacology Review(s)	
Statistical Review(s)	
Microbiology Review(s)	
Clinical Pharmacology/Biopharmaceutics Review(s)	
Risk Assessment and Risk Mitigation Review(s)	
Proprietary Name Review(s)	
Other Review(s)	
Administrative/Correspondence Document(s)	**X**

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

NDA 022410/S-011

APPROVAL LETTER

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDAs 18401/ S-019, 20732/S-009, 20733/ S-011 & 22410/ S-011bundle

APPROVAL LETTER

Reckitt Benckiser Pharmaceuticals, Inc.
Attention: Vanita Dimri, RAC, ASQ-CQA
Regulatory Affairs-RegEx NA
10710 Midlothian Turnpike, Suite 430
Richmond VA 23235

Dear Ms. Dimri:

Please refer to your Supplemental New Drug Application (sNDA), submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for the following:

NDA	Supplement	Drug Product	Dated	Received
18401	S-019	Buprenex® (buprenorphine HCI) Injection	March 15, 2013	March 18, 2013
20732	S-009	Subutex® (buprenorphine HCI) Sublingual Tablet	March 15, 2013	March 18, 2013
20733	S-011	Suboxone® (buprenorphine HCI/ naloxone HCI) Sublingual Tablet	March 15, 2013	March 18, 2013
22410	S-011	Suboxone® (buprenorphine HCI/ naloxone HCI) Sublingual film	March 15, 2013	March 15, 2013

These "Changes Being Effected" supplements provide to register post approval drug substance changes made to the manufacture of drug substance Buprenorphine HCl, in DMF 12412.

We have completed our review of these supplemental new drug applications. These supplements are approved.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call LCDR Luz E Rivera, Regulatory Project Manager, at (301) 796-4013.

Sincerely,

{See appended electronic signature page}

Ramesh Raghavachari, Ph.D.
Acting Branch Chief, Branch IX
Division of New Drug Quality Assessment III
Office of New Drug Quality Assessment
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

RAMESH RAGHAVACHARI
08/08/2013

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

NDA 022410/S-011

CHEMISTRY REVIEW(S)

Chemistry Review:# 1	**1. Division:** ONDQA-DAAAP	**2. NDA Number: (**a) 20-733 S011, (b) 20-732 S009, (c) 18-401 S019 (d) 22-410 S011
3. Name and Address of Applicant: RECKITT BENCKISER 10710 Midlothian Turnpike Richmond VA 23235		**4. Supplement(s):** CBE-0 **Number:** Refer to NDA number **Date(s):** 02/25/2013 **PDUFA Date:** 09/18/2013
5. Name of Drug: (a) Suboxone® (buprenorphine HCl/Naloxone HCl), sublingual tablets (b) Subutex® (buprenorphine HCl), sublingual tablets, (c) Buprenex® injection (buprenorphine HCl) (d) Suboxone® (buprenorphine HCl/Naloxone HCl) Sublingual Film		**6. Nonproprietary name:** Buprenorphine HCl
7. Supplement Provides for: incorporation of CMC changes made to manufacture of drug substance Buprenorphine HCl, in DMF 12412.		**8. Amendment(s):**
9. Pharmacological Category: mu-opioid receptor partial agonist and a kappa-opioid receptor antagonist	**10. How Dispensed:** R_x	**11. Related Documents:** DMF12412
12. Dosage Form: Refer to Name of Drug	**13. Potency:** 2 mg and 8 mg	

14. Chemical Name and Structure:

Buprenorphine HCl: 6 (2S)-2-[17-Cyclopropylmethyl-4,5α-epoxy-3-hydroxy-6-methoxy-6α,14-ethano-14α-morphinan-7α-yl]-3,3dimethylbutan-2-ol hydrochloride; CAS: [53152-21-9]; $C_{29}H_{41}NO_4 \cdot HCl$; MW = 504.10



Nalonxone HCl: 17-Allyl-4, 5 α -epoxy-3, 14-dihydroxymorphinan-6-one hydrochloride dihydrate; CAS: [357-08-4]; $C_{19}H_{21}NO_4 \bullet HCl \bullet 2H_2O$; MW = 399.87



15. Comments:

- Incorporation of CMC changes made to drug substance, buprenorphine HCl in DMF 12412 to NDA
- LOA provided 3/10/2013

16. Conclusion: This supplement is recommended for approval from CMC perspective

17. Name:	**Signature:**	**Date:**
Erika E. Englund, Ph.D., Chemist		
18. Concurrence:	**Signature:**	**Date:**
Ramesh Raghavachari, Ph.D., Acting Branch Chief, Br., IX, ONDQA		

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ERIKA E ENGLUND
08/07/2013

RAMESH RAGHAVACHARI
08/07/2013

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

NDA 022410/S-011

ADMINISTRATIVE and CORRESPONDENCE DOCUMENTS

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDAs 18401/ S-019, 20732/S-009, 20733/ S-011 & 22410/ S-011 bundle

GENERAL CORRESPONDENCE

Reckitt Benckiser Pharmaceuticals, Inc.
Attention: Vanity Dimri, RAC, ASQ, CQA
Regulatory Affairs
10710 Midlothian Turnpike
Richmond VA 23235

Dear Ms. Dimri:

Please refer to your supplemental new drug applications submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for the following:

NDA	Supplement	Drug Product	Dated	Received
18401	S-019	Buprenex Injectable (buprenorphine HCI)	March 15, 2013	March 18, 2013
20732	S-009	Subutex Sublingual Tablet (buprenorphine HCI)	March 15, 2013	March 18, 2013
20733	S-011	Suboxone Sublingual Tablet (buprenorphine HCI/ naloxone HCI dihydrate)	March 15, 2013	March 18, 2013
22410	S-011	Suboxone Sublingual film (buprenorphine HCI/ naloxone HCI dihydrate	March 15, 2013	March 15, 2013

The March 22, 2013 Acknowledgement letter did not include sNDA 22410/ S-011, dated and received March 15, 2013. These "Changes Being Effected" supplements propose to register post approval drug substance changes.

Unless we notify you within 60 days of the receipt date that the applications are not sufficiently complete to permit a substantive review, we will file the applications on the new date of May 15, 2013 not May 27, 2013, in accordance with 21 CFR 314.101(a). If the applications are filed, the user fee goal date will be September 15, 2013 not September 18, 2013 as was indicated on the March 22, 2013 acknowledgement letter.

If you have any questions, call LCDR Luz E Rivera, Regulatory Project Manager, at (301) 796 4013.

Sincerely,

{See appended electronic signature page}

Ramesh Raghavachari, Ph.D.
Acting Branch Chief, Branch IX
Division of New Drug Quality Assessment III
Office of New Drug Quality Assessment
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

RAMESH RAGHAVACHARI
04/02/2013